Inhibition of amyloid fibrillation and cytotoxicity of lysozyme fibrillation products by polyphenols

International Journal of Biological Macromolecules

Volumn 80, Issue , 2015, Pages 95-106

  Shariatizi, Sajad ^a   Meratan, Ali Akbar ^b   Ghasemi, Atiyeh ^a   Nemat Gorgani, Mohsen ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b Agricultural and Natural Resources University of Ramin   (Iran)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti amyloidogenic; Fibrillation products cytotoxicity; Polyphenol

Indexed keywords

AMYLOID; LYSOZYME; RESVERATROL; ROSMARINIC ACID; THIOFLAVINE; ANTIOXIDANT; CINNAMIC ACID DERIVATIVE; DEPSIDE; STILBENE DERIVATIVE;

AMYLOIDOSIS; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CELL VIABILITY; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON MICROSCOPY; FLUORESCENCE ANALYSIS; HEN; HYDROPHOBICITY; MTT ASSAY; NEUROPROTECTION; NONHUMAN; PC12 CELL LINE; PROTEIN AGGREGATION; PROTEIN SECONDARY STRUCTURE; RAT; ANIMAL; CELL SHAPE; CELL SURVIVAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; IC50; PRECLINICAL STUDY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN STABILITY;

AMYLOID; ANIMALS; ANTIOXIDANTS; CELL SHAPE; CELL SURVIVAL; CINNAMATES; DEPSIDES; DRUG EVALUATION, PRECLINICAL; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITORY CONCENTRATION 50; MURAMIDASE; PC12 CELLS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RATS; STILBENES;

EID: 84932598978     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.06.030     Document Type: Article

References (85)

1. Bartolini M., Andrisano V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 2010, 11:1018-1035.
2. Bieschke J., Herbst M., Wiglenda T., Friedrich R.P., Boeddrich A., Schiele F., Kleckers D., Lopez del Amo J.M., Grüning B.A., Wang Q., Schmidt M.R., Lurz R., Anwyl R., Schnoegl S., Fandrich M., Frank R.F., Reif B., Gunther S., Walsh D.M., Wanker E.E. Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat. Chem. Biol. 2012, 8:93-101.
3. Gazit E. Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool. FEBS J. 2005, 272:5971-5978.
4. Uversky V.N., Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 2004, 1698:131-153.
5. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
6. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science 2003, 300:486-489.
7. Ladiwala A.R., Dordick J.S., Tessier P.M. Aromatic small molecules remodel toxic soluble oligomers of amyloid through three independent pathways. J. Biol. Chem. 2011, 286:3209-3218.
8. Roychaudhuri R., Yang M., Hoshi M.M., Teplow D.B. Amyloid beta-protein assembly and Alzheimer disease. J. Biol. Chem. 2009, 284:4749-4753.
9. Cohen F.E., Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426:905-909.
10. Härd T., Lendel C. Inhibition of amyloid formation. J. Mol. Biol. 2012, 421:441-465.
11. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:49-60.
12. Gazova Z., Siposova K., Kurin E., Mučaji P., Nagy M. Amyloid aggregation of lysozyme: the synergy study of red wine polyphenols. Proteins 2013, 81:994-1004.
13. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., Hisanaga S., Goedert M., Hasegawa M. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 2006, 45:6085-6094.
14. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today 1999, 5:343-350.
15. Wang J.B., Wang Y.M., Zeng C.M. Quercetin inhibits amyloid fibrillation of bovine insulin and destabilizes preformed fibrils. Biochem. Biophys. Res. Commun. 2011, 415:675-679.
16. De Felice F.G., Ferreira S.T. β-Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell. Mol. Neurobiol. 2002, 22:545-563.
17. Amijee H., Scopes D.I. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J. Alzheimers Dis. 2009, 17:33-47.
18. Cohen T., Frydman-Marom A., Rechter M., Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 2006, 45:4727-4735.
19. De Felice F.G., Houzel J.C., Garcia-Abreu J., Louzada P.R., Afonso R.C., Meirelles M.N., Lent R., Neto V.M., Ferreira S.T. Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitro phenols: implications for Alzheimer's therapy. FASEB J. 2001, 15:1297-1299.
20. Ebrahimi A., Schluesener H. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res. Rev. 2012, 11:329-345.
21. Hamaguchi T., Ono K., Murase A., Yamada M. Phenolic compounds prevent Alzheimers pathology through different effects on the amyloid-β aggregation pathway. Am. J. Pathol. 2009, 175:2557-2565.
22. Porat Y., Abramowitz A., Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 2006, 67:27-37.
23. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol. 2006, 545:51-64.
24. Ehrnhoefer D.E., Duennwald M., Markovic P., Wacker J.L., Engemann S., Roark M., Legleiter J., Marsh J.L., Thompson L.M., Lindquist S., Muchowski P.J., Wanker E.E. Green tea (2)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 2006, 15:2743-2751.
25. Ferreira N., Saraiva M.J., Almeida M.R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett. 2011, 585:2424-2430.
26. Hafner-Bratkovic I., Gaspersic J., Smid L.M., Bresjanac M., Jerala R. Curcumin binds to the α-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP (Sc) accumulation. J. Neurochem. 2008, 104:1553-1564.
27. Mishra R., Sellin D., Radovan D., Gohlke A., Winter R. Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol. ChemBioChem 2009, 10:445-449.
28. Ono K., Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. J. Neurochem. 2006, 97:105-115.
29. Rivière C., Richard T., Vitrac X., Mérillon J.M., Valls J., Monti J.P. New polyphenols active on β-amyloid aggregation. Bioorg. Med. Chem. Lett. 2008, 18:828-831.
30. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
31. Zhu M., Rajamani S., Kaylor J., Han S., Zhou F., Fink A.L. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 2004, 279:26846-26857.
32. Ghobeh M., Ahmadian S., Meratan A.A., Ebrahim-Habibi A., Ghasemi A., Shafizadeh M., Nemat-Gorgani M. Interaction of Aβ(25-35) fibrillation products with mitochondria: effect of small-molecule natural products. Biopolymers 2014, 102:473-486.
33. Krebs M.R., Wilkins D.K., Chung E.W., Pitkeathly M.C., Chamberlain A.K., Zurdo J., Robinson C.V., Dobson C.M. Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the β-domain. J. Mol. Biol. 2000, 300:541-549.
34. Pepys M.B., Hawking P.N., Booth D.R., Vigushin D.M., Tennent G.A., Soutar A.K., Totty N., Nguyen O., Blake C.C., Terry C.J., Feest T.G., Zalin A.M., Hsuan J.J. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993, 362:553-557.
35. Morshedi D., Rezaei-Ghaleh N., Ebrahim-Habibi A., Ahmadian S., Nemat-Gorgani M. Inhibition of amyloid fibrillation of lysozyme by indole derivatives: possible mechanism of action. FEBS J. 2007, 274:6415-6425.
36. He J., Wang Y., Chang A.K., Xu L., Wang N., Chong X., Li H., Zhang B., Jones G.W., Song Y. Myricetin prevents fibrillogenesis of hen egg white lysozyme. J. Agric. Food Chem. 2014, 62:9442-9449.
37. Ghosh S., Pandey N.K., Dasgupta S. (-)-Epicatechin gallate prevents alkali-salt mediated fibrillogenesis of hen egg white lysozyme. Int. J. Biol. Macromol. 2013, 54:90-98.
38. Borana M.S., Mishra P., Pissurlenkar R.R., Hosur R.V., Ahmad B. Curcumin and kaempferol prevent lysozyme fibril formation by modulating aggregation kinetic parameters. Biochim. Biophys. Acta 2014, 1844:670-680.
39. He J., Xing Y.F., Huang B., Zhang Y.Z., Zeng C.M. Tea catechins induce the conversion of preformed lysozyme amyloid fibrils to amorphous aggregates. J. Agric. Food Chem. 2009, 57:11391-11396.
40. Lee H.J., Cho H.S., Park E., Kim S., Lee S.Y., Kim C.S., Kim do K., Kim S.J., Chun H.S. Rosmarinic acid protects human dopaminergic neuronal cells against hydrogen peroxide-induced apoptosis. Toxicology 2008, 250:109-115.
41. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273:21875-21882.
42. Feng Y., Wang X.P., Yang S.G., Wang Y.J., Zhang X., Du X.T., Sun X.X., Zhao M., Huang L., Liu R.T. Resveratrol inhibits β-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. NeuroToxicology 2009, 30:986-995.
43. Iuvone T., De Filippis D., Esposito G., D'Amico A., Izzo A.A. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J. Pharmacol. Exp. Ther. 2006, 317:1143-1149.
44. Jang J.H., Surh Y.J. Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 2003, 34:1100-1110.
45. Ono K., Hasegawa K., Naiki H., Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75:742-750.
46. Meratan A.A., Ghasemi A., Nemat-Gorgani M. Membrane integrity and amyloid cytotoxicity: a model study involving mitochondria and lysozyme fibrillation products. J. Mol. Biol. 2011, 409:826-838.
47. Arnaudov L.N., de Vries R. Thermally induced fibrillar aggregation of hen egg white lysozyme. Biophys. J. 2005, 88:515-526.
48. Goldberg M.E., Rudolph R., Jaenicke R. A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme. Biochemistry 1991, 30:2790-2797.
49. Hunaefi D., Smetanska I. The effect of tea fermentation on rosmarinic acid and antioxidant properties using selected in vitro sprout culture of Orthosiphon aristatus as a model study. SpringerPlus 2013, 2:167.
50. Bonda C., Zhang J., Pavlovic A. The photostability and photostabilization of trans-resveratrol. Cosmet. Toiletries 2011, 126:652-660.
51. Gibson T.J., Murphy R.M. Inhibition of insulin fibrillogenesis with targeted peptides. Protein Sci. 2006, 15:1133-1141.
52. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., Uversky V.N., Fink A.L. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001, 40:6036-6046.
53. Vistica D.T., Skehan P., Scudiero D., Monks A., Pittman A., Boyd M.R. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 1999, 51:2515-2520.
54. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992, 5:227-231.
55. Frare E., Mossuto M.F., de Laureto P.P., Tolin S., Menzer L., Dumoulin M., Dobson C.M., Fontana A. Characterization of oligomeric species on the aggregation pathway of human lysozyme. J. Mol. Biol. 2009, 387:17-27.
56. Kremer J.J., Pallitto M.M., Sklansky D.J., Murphy R.M. Correlation of β-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 2000, 39:10309-10318.
57. Bastianetto S., Krantic S., Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimers disease. Mini Rev. Med. Chem. 2008, 8:429-435.
58. Ono K., Yoshiike Y., Takashima A., Hasegawa K., Naiki H., Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 2003, 87:172-181.
59. Ono K., Hasegawa K., Naiki H., Yamada M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro. Biochim. Biophys. Acta 2004, 1690:193-202.
60. Gazit E. A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J. 2002, 16:77-83.
61. De Felice F.G., Vieira M.N., Saraiva L.M., Figueroa-Villar J.D., Garcia-Abreu J., Liu R., Chang L., Klein W.L., Ferreira S.T. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 2004, 18:1366-1372.
62. Riviere C., Richard T., Vitrac X., Merillon J.M., Valls J., Monti J.P. New polyphenols active on beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 2008, 18:828-831.
63. Ono K., Hamaguchi T., Naiki H., Yamada M. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim. Biophys. Acta 2006, 1762:575-586.
64. Shoval H., Weiner L., Gazit E., Levy M., Pinchuk I., Lichtenberg D. Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS. Biochim. Biophys. Acta 2008, 1784:1570-1577.
65. Rattanajarasroj S., Unchern S. Comparable attenuation of Abeta (25-35)-induced neurotoxicity by quercitrin and 17beta-estradiol in cultured rat hippocampal neurons. Neurochem. Res. 2010, 35:1196-1205.
66. Kim J., Lee H.J., Lee K.W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J. Neurochem. 2010, 112:1415-1430.
67. Lemkul J.A., Bevan D.R. Destabilizing Alzheimer's Aβ42 protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry 2010, 49:3935-3946.
68. Shoval H., Lichtenberg D., Gazit E. The molecular mechanisms of the anti-amyloid effects of phenols. Amyloid 2007, 14:73-87.
69. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., Endo N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. J. Biol. Chem. 1996, 271:6839-6844.
70. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 2005, 280:7614-7623.
71. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277:32046-32053.
72. Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., Morozova-Roche L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol. 2007, 365:1337-1349.
73. Novitskaya V., Bocharova O.V., Bronstein I., Baskakov I.V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 2006, 281:13828-13836.
74. Guerrero-Munoz M.J., Castillo-Carranza D.L., Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem. Pharmacol. 2014, 88:468-478.
75. Zhua X., Sua B., Wanga X., Smitha M.A., Perrya G. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 2007, 64:2202-2210.
76. Zhao B. Natural antioxidants for neurodegenerative diseases. Mol. Neurobiol. 2005, 31:283-294.
77. Heo H.J., Kim D.O., Choi S.J., Shin D.H., Lee C.Y. Potent inhibitory effect of flavonoids in Scutellaria baicalensis on amyloid beta protein-induced neurotoxicity. J. Agric. Food Chem. 2004, 52:4128-4132.
78. Jiménez-Aliaga K., Bermejo-Bescós P., Benedí J., Martín-Aragón S. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci. 2011, 89:939-945.
79. Sultana R., Ravagna A., Mohmmad-Abdul H., Calabrese V., Butterfield D.A. Ferulic acid ethyl ester protects neurons against amyloid beta-peptide (1-42) induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J. Neurochem. 2005, 92:749-758.
80. Bastianetto S., Yao Z.X., Papadopoulos V., Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur. J. Neurosci. 2006, 23:55-64.
81. Ngoungoure V.L., Schluesener J., Moundipa P.F., Schluesener H. Natural polyphenols binding to amyloid: a broad class of compounds to treat different human amyloid diseases. Mol. Nutr. Food Res. 2015, 59:8-20.
82. Ladiwala A.R., Lin J.C., Bale S.S., Marcelino-Cruz A.M., Bhattacharya M., Dordick J.S., Tessier P.M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J. Biol. Chem. 2010, 285:24228-24237.
83. Takahashi R., Ono K., Takamura Y., Mizuguchi M., Ikeda T., Nishijo H., Yamada M. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity. J. Neurochem. 2015, 10.1111/jnc.13180.
84. Hudson S.A., Ecroyd H., Dehle F.C., Musgrave I.F., Carver J.A. (-)-Epigallocatechin-3-gallate (EGCG) maintains κ-casein in its pre-fibrillar state without redirecting its aggregation pathway. J. Mol. Biol. 2009, 392:689-700.
85. Hamaguchi T., Ono K., Murase A., Yamada M. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-β aggregation pathway. Am. J. Pathol. 2009, 175:2557-2565.